Life-Threatening ACE Inhibitor-Induced Angioedema After Eleven Years on Lisinopril

2012 ◽  
Vol 26 (4) ◽  
pp. 382-388 ◽  
Author(s):  
Johanna L. Norman ◽  
Whitney L. Holmes ◽  
William A. Bell ◽  
Shannon W. Finks
Keyword(s):  
Ace Inhibitor ◽  
Treatment Initiation ◽  
Enzyme Inhibitors ◽  
African American Woman ◽  
American Woman ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Single Treatment ◽  
Converting Enzyme Inhibitors ◽  
Life Threatening

Angiotensin-converting enzyme inhibitors (ACE-Is) are the primary medication class implicated in drug-associated angioedema. Angioedema is most common early in ACE-I therapy, yet episodes can occur late in therapy and have been reported even as late as 10 years after single treatment initiation. We present a case of a 65-year-old African American woman who experienced 2 episodes of angioedema, with the second being life threatening after receiving several concomitant agents known to cause angioedema, most notably lisinopril for 11 years.

scholarly journals Življenje ogrožajoč angioedem po zaviralcu angiotenzinove konvertaze: prikaz dveh primerov Life-threatening angioedema induced by angiotensin-converting enzyme inhibitor: two case reports

2016 ◽  
Vol 84 (12) ◽  
Author(s):  
Erik Rupnik ◽  
Stojan Kariž ◽  
Črtomir Iglič ◽  
Mihaela Zidarn
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Case Reports ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Key Enzyme ◽  
Life Threatening

Background. Angioedema is a rare but potentially very serious complication of treatment with angiotensin converting enzyme inhibitors (ACEI). Angioedema is due to the accumulation of bradykinin, because angiotensin converting enzyme is the key enzyme for its degradation.Case reports. We present two patients with life-threatening angioedema while taking ACEI. Both patients had already had episodes of angioedema. Angioedema didn't respond to adrenaline. In both patients intubation was difficult.Conclusion. In the acute phase of angioedema due to ACEI it is necessary to protect the airways. Bradykinin receptor inhibitors shorten the duration of episodes of angioedema. In the long term it is essential to permanently avoid ACEI.

scholarly journals Angiotensin-converting Enzyme Inhibitors-induced Angioedema

2018 ◽  
Vol 4 (1) ◽  
pp. 47-50 ◽  
Author(s):  
Anca Chiriac ◽  
Piotr Brzezinski ◽  
Mircea Betiu ◽  
Liliana Foia
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Adverse Reactions ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Cardiovascular Disorders ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Acquired Angioedema ◽  
Life Threatening

Abstract Angiotensin-converting enzyme inhibitors (ACEI) are widely used drugs nowadays in treating patients diagnosed with cardiovascular disorders. We present two consecutive cases of acquired angioedema caused by the administration of enalapril and lisinopril in patients with indication for ACE-inhibitors therapy. Rigorous follow-up of side effects of ACEI is required, due to these possible life-threatening adverse reactions.

Use of Baclofen to Suppress Cough Induced by Angiotensin-Converting Enzyme Inhibitors

1996 ◽  
Vol 30 (11) ◽  
pp. 1242-1245 ◽  
Author(s):  
Peter V Dicpinigaitis
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Low Dose ◽  
Ace Inhibitor ◽  
Enzyme Inhibitors ◽  
Study Drug ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Open Label ◽  
Converting Enzyme Inhibitors ◽  
Dose Oral

OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors. DESIGN: Prospective, open-label, clinical trial of a 4-week course of low-dose oral baclofen (5 mg tid days 1–7, 10 mg tid days 8–28). SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough. SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy. RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3–6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5–15). In addition, all subjects demonstrated persistent suppression of cough (range 25–74 d) after discontinuation of the study drug. CONCLUSIONS: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.

Angioedema secondary to angiotensin-converting enzyme inhibitors

1994 ◽  
Vol 108 (8) ◽  
pp. 696-698 ◽  
Author(s):  
J. P. M. Pracy ◽  
J. A. McGlashan ◽  
R. M. Walsh ◽  
M. J. Gleeson
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Cardiac Failure ◽  
Ace Inhibitors ◽  
Side Effect ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Threatening Condition ◽  
Life Threatening

AbstractAngioedema secondary to angiotensin-converting enzyme (ACE) inhibitors is rare, but it is a side effect which is likely to be seen more frequently because of the increased use of these drugs to treat cardiac failure and hypertension. Presentation is variable and the diagnosis may go unrecognized for many months or years. The cases reported illustrate problems both in the diagnosis and management of this life-threatening condition.

Sign in / Sign up

Export Citation Format

Share Document